GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Selling, General, & Admin. Expense

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Selling, General, & Admin. Expense : $76.91 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Calliditas Therapeutics AB's selling, general, & admin. expense for the three months ended in Dec. 2023 was $28.58 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was $76.91 Mil.


Calliditas Therapeutics AB Selling, General, & Admin. Expense Historical Data

The historical data trend for Calliditas Therapeutics AB's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Selling, General, & Admin. Expense Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only 6.67 16.95 42.93 74.64 103.41

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.15 26.30 24.94 23.38 28.58

Competitive Comparison of Calliditas Therapeutics AB's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Calliditas Therapeutics AB's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calliditas Therapeutics AB's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Selling, General, & Admin. Expense falls into.



Calliditas Therapeutics AB Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $76.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB  (NAS:CALT) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Calliditas Therapeutics AB Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.